Document is current

Article History

Received: 18 March 2022

Accepted: 6 February 2023

First Online: 22 February 2023

Declarations

:

: Not applicable.

: Not applicable.

: AM and JC are employees of Mereo BioPharma Group, London, United Kingdom and receive stock options. SP and MR are employees of Wickenstones Ltd, Abingdon, United Kingdom. LB was employed by Wickenstones Ltd, Abingdon, United Kingdom but has since left the company. MB and CR have received payments for their contributions to the present manuscript. MB has received grants and from Ultragenyx Pharmaceuticals Inc, Novato, USA. and the Osteogenesis Imperfecta Foundation. TH serves as the Chief Executive Officer of the Osteogenesis Imperfecta Foundation and has received unrestricted educational grants from Mereo BioPharma Group London, United Kingdom and Ultragenyx Pharmaceuticals Inc, Novato, USA. OS has participated in a national advisory board for Mereo BioPharma Group London, United Kingdom. FR has received study contracts for experimental preclinical studies with Precithera Inc, Quebec, Canada, Mesentech Inc, Vancouver, Canada and Catabasis Pharmaceuticals Inc, Cambridge, USA. He has participated in advisory boards for Ultragenyx Pharmaceuticals Inc, Novato, USA, Sanofi S.A. Paris, France, Novartis International AG, Basel, Switzerland and Mereo BioPharma Group, London, United Kingdom. FR has received a speaker fee from Ultragenyx Pharmaceuticals Inc, Novato, USA for a lecture and received a donation of experimental drugs for a preclinical study from Acceleron Pharma Inc, Cambridge, USA. CR received an institutional grant from BioMarin Pharmaceuticals Inc, Novato, California, has participated in advisory boards for Ultragenyx Pharmaceuticals Inc, Novato, USA and sits on the medical board of the Osteogenesis Imperfecta Foundation. TW and IW hold leadership positions in the Osteogenesis Imperfecta Foundation Europe, which has received grants from Mereo BioPharma Group, London, United Kingdom.